Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genelux Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Verastem, Inc.
BeOne Medicines
Centre Oscar Lambret
Incyte Corporation
Novartis
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
GlaxoSmithKline
Tesaro, Inc.
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Daiichi Sankyo
AstraZeneca
Genmab
Genmab
AstraZeneca
Imunon
Institut Claudius Regaud
Seagen Inc.
AbbVie
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
University of California, San Diego
National Cancer Center, Korea
Tata Memorial Hospital
Merck Sharp & Dohme LLC
Daiichi Sankyo
Merck Sharp & Dohme LLC
BioNTech SE
Imperial College London
Impact Therapeutics, Inc.
Amgen
University Health Network, Toronto
AstraZeneca
Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca
AstraZeneca
Gilead Sciences